JP2016505012A - Ｉｒａｋ阻害剤およびその使用 - Google Patents

Ｉｒａｋ阻害剤およびその使用 Download PDF

Info

Publication number
JP2016505012A
JP2016505012A JP2015552741A JP2015552741A JP2016505012A JP 2016505012 A JP2016505012 A JP 2016505012A JP 2015552741 A JP2015552741 A JP 2015552741A JP 2015552741 A JP2015552741 A JP 2015552741A JP 2016505012 A JP2016505012 A JP 2016505012A
Authority
JP
Japan
Prior art keywords
compound
ring
nitrogen
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505012A5 (enExample
Inventor
ジェレミー ロバート グレーンウッド，
ジェレミー ロバート グレーンウッド，
ジェラルディーン シー． ハリマン，
ジェラルディーン シー． ハリマン，
ロサナ カペラー−リバーマン，
ロサナ カペラー−リバーマン，
クレッグ イー． マッス，
クレッグ イー． マッス，
ショーネッシー ロビンソン，
ショーネッシー ロビンソン，
ドナ エル． ロメロ，
ドナ エル． ロメロ，
ミー シェリー，
ミー シェリー，
ロナルド ティー． ウェスタ—，
ロナルド ティー． ウェスタ―，
Original Assignee
ニンバス アイリス， インコーポレイテッド
ニンバス アイリス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニンバス アイリス， インコーポレイテッド, ニンバス アイリス， インコーポレイテッド filed Critical ニンバス アイリス， インコーポレイテッド
Publication of JP2016505012A publication Critical patent/JP2016505012A/ja
Publication of JP2016505012A5 publication Critical patent/JP2016505012A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015552741A 2013-01-10 2014-01-08 Ｉｒａｋ阻害剤およびその使用 Pending JP2016505012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751000P 2013-01-10 2013-01-10
US61/751,000 2013-01-10
PCT/US2014/010652 WO2014110114A1 (en) 2013-01-10 2014-01-08 Irak inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2016505012A true JP2016505012A (ja) 2016-02-18
JP2016505012A5 JP2016505012A5 (enExample) 2017-02-09

Family

ID=51061425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552741A Pending JP2016505012A (ja) 2013-01-10 2014-01-08 Ｉｒａｋ阻害剤およびその使用

Country Status (9)

Country Link
US (2) US9175007B2 (enExample)
EP (1) EP2943202A4 (enExample)
JP (1) JP2016505012A (enExample)
CN (1) CN105142639A (enExample)
AU (1) AU2014205577A1 (enExample)
BR (1) BR112015014034A2 (enExample)
CA (1) CA2890911A1 (enExample)
HK (1) HK1216859A1 (enExample)
WO (1) WO2014110114A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019383845B2 (en) * 2018-11-21 2023-02-02 Korea Research Institute Of Chemical Technology Novel tricyclic compound as IRAK4 inhibitor

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014110114A1 (en) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
BR112017001677A2 (pt) * 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2019001461A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 Irak4抑制剂
JP7167069B2 (ja) * 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
AU2019212969B2 (en) * 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
AU2019389174A1 (en) * 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20220252574A1 (en) * 2019-07-22 2022-08-11 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2023075479A1 (ko) * 2021-10-28 2023-05-04 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
ES3075943T3 (en) 2022-03-23 2026-08-10 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1937459A1 (de) 1968-08-02 1970-02-05 Ciba Geigy Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
CA2365578A1 (en) 1999-03-30 2000-10-12 Seiichi Uchida Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN101100472A (zh) * 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
WO2003057149A2 (en) 2001-12-28 2003-07-17 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
BRPI0408988A (pt) 2003-03-31 2006-03-28 Predix Pharmaceuticals Holding composto de piperidinilamino-tieno[2,3-d]pirimidina
WO2005037213A2 (en) 2003-10-14 2005-04-28 Cornell Research Foundation, Inc. Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
ATE455777T1 (de) 2004-07-23 2010-02-15 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
AU2006261082B2 (en) 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
JP2009504752A (ja) 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式ｍＧｌｕＲ１アンタゴニスト
ATE516292T1 (de) 2005-08-19 2011-07-15 Schering Corp Kondensierte tricyclische mglur1-antagonisten als therapeutische mittel
EP2132211A4 (en) * 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
AR073739A1 (es) 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
CA2783701A1 (en) 2009-12-10 2011-06-16 The University Of North Carolina At Chapel Hill Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
CN103119047B (zh) 2010-07-23 2016-06-15 哈佛大学校长及研究员协会 三环类蛋白酶体活性增强化合物
IN2014CN04558A (enExample) 2011-11-23 2015-09-18 Cancer Rec Tech Ltd
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
HK1210732A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014110114A1 (en) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014194245A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
WO2014194242A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019383845B2 (en) * 2018-11-21 2023-02-02 Korea Research Institute Of Chemical Technology Novel tricyclic compound as IRAK4 inhibitor
US12378250B2 (en) 2018-11-21 2025-08-05 Korea Research Institute Of Chemical Technology Tricyclic compound as IRAK4 inhibitor

Also Published As

Publication number Publication date
BR112015014034A2 (pt) 2017-07-11
HK1216859A1 (zh) 2016-12-09
AU2014205577A1 (en) 2015-05-28
US20140194417A1 (en) 2014-07-10
EP2943202A4 (en) 2016-08-24
WO2014110114A1 (en) 2014-07-17
CA2890911A1 (en) 2014-07-17
US20160068543A1 (en) 2016-03-10
US9751892B2 (en) 2017-09-05
US9175007B2 (en) 2015-11-03
CN105142639A (zh) 2015-12-09
EP2943202A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
US9751892B2 (en) IRAK inhibitors and uses thereof
US9518065B2 (en) IRAK inhibitors and uses thereof
US9790234B2 (en) IRAK inhibitors and uses thereof
US10968236B2 (en) TYK2 inhibitors and uses thereof
JP6126131B2 (ja) Ｉｒａｋ阻害剤およびその使用
US9067948B2 (en) IRAK inhibitors and uses thereof
US9340554B2 (en) IRAK inhibitors and uses thereof
WO2017004133A1 (en) Irak inhibitors and uses thereof
JP2017513954A (ja) Ｉｒａｋ阻害剤およびその使用
US20140018361A1 (en) Irak inhibitors and uses thereof
WO2017004134A1 (en) Irak inhibitors and uses thereof
WO2014194242A2 (en) Flt3 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180629